TBPL2 and cervical cancer: The findings here demonstrate that a better way to use a gene editing system consisting of TBP2 and therapeutic plasmids in gene therapy is via local administration, for example, in cases of cervical cancer and nasopharyngeal carcinoma, wherein therapy can be administered directly through vagina and nasal routes.